Published in PLoS One on September 25, 2014
Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov (2015) 1.18
Construction and analysis of cardiac hypertrophy-associated lncRNA-mRNA network based on competitive endogenous RNA reveal functional lncRNAs in cardiac hypertrophy. Oncotarget (2016) 0.86
Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. J Am Coll Cardiol (2016) 0.85
Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget (2016) 0.82
The Role of Nonhuman Primate Animal Models in the Clinical Development of Pluripotent Stem Cell Therapies. Mol Ther (2016) 0.81
Molecular Approaches in HFpEF: MicroRNAs and iPSC-Derived Cardiomyocytes. J Cardiovasc Transl Res (2016) 0.79
Comprehensive evaluation of AmpliSeq transcriptome, a novel targeted whole transcriptome RNA sequencing methodology for global gene expression analysis. BMC Genomics (2015) 0.77
Common miR-590 Variant rs6971711 Present Only in African Americans Reduces miR-590 Biogenesis. PLoS One (2016) 0.77
Prospects for In Vitro Myofilament Maturation in Stem Cell-Derived Cardiac Myocytes. Biomark Insights (2015) 0.77
Cellular Therapy for Heart Failure. Curr Cardiol Rev (2016) 0.75
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes. Clin Transl Med (2017) 0.75
MiR-590 Promotes Transdifferentiation of Porcine and Human Fibroblasts Toward a Cardiomyocyte-Like Fate by Directly Repressing Specificity Protein 1. J Am Heart Assoc (2016) 0.75
mirPRo-a novel standalone program for differential expression and variation analysis of miRNAs. Sci Rep (2015) 0.75
G-protein Coupled Receptor Signaling in Pluripotent Stem Cell-derived Cardiovascular Cells: Implications for Disease Modeling. Front Cell Dev Biol (2015) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Differential expression analysis for sequence count data. Genome Biol (2010) 64.56
miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res (2006) 39.25
miRBase: tools for microRNA genomics. Nucleic Acids Res (2007) 38.61
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
The microRNA Registry. Nucleic Acids Res (2004) 29.45
miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res (2010) 25.85
miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res (2013) 13.41
WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res (2005) 12.88
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 10.09
Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res (2009) 7.09
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res (2013) 6.17
Rfam 11.0: 10 years of RNA families. Nucleic Acids Res (2012) 6.14
Pervasive roles of microRNAs in cardiovascular biology. Nature (2011) 6.08
miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades. Nucleic Acids Res (2011) 5.83
miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res (2010) 5.72
MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res (2007) 5.65
psRNATarget: a plant small RNA target analysis server. Nucleic Acids Res (2011) 5.45
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest (2009) 4.39
The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res (2006) 4.38
Signaling pathways for cardiac hypertrophy and failure. N Engl J Med (1999) 3.97
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
SHRiMP2: sensitive yet practical SHort Read Mapping. Bioinformatics (2011) 3.82
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68
What is the role of beta-adrenergic signaling in heart failure? Circ Res (2003) 3.22
High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol (2011) 2.65
Developing microRNA therapeutics. Circ Res (2012) 2.58
miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A (2009) 2.33
MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol (2009) 2.18
Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol (1999) 1.83
MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr Biol (1999) 1.62
MicroRNAs in control of cardiac hypertrophy. Cardiovasc Res (2012) 1.44
MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. Circ Res (2013) 1.39
Glucose metabolism and cardiac hypertrophy. Cardiovasc Res (2011) 1.28
Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci (2010) 1.14
Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res (2002) 1.06
Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res (1999) 1.02
Gq-initiated cardiomyocyte hypertrophy is mediated by phospholipase Cbeta1b. FASEB J (2009) 1.01
Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J Biol Chem (2011) 0.96
p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cell Signal (2012) 0.96
Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy. J Biomol Screen (2013) 0.96
microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood) (2011) 0.92
Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones. Endocr J (2010) 0.91
C-Myc induced compensated cardiac hypertrophy increases free fatty acid utilization for the citric acid cycle. J Mol Cell Cardiol (2012) 0.89
Stem cells and their derivatives: a renaissance in cardiovascular translational research. J Cardiovasc Transl Res (2011) 0.89
Cardiac natriuretic peptides: from basic discovery to clinical practice. Cardiovasc Ther (2010) 0.86
Role of endothelin in the induction of cardiac hypertrophy in vitro. PLoS One (2012) 0.81
Common pathways for primary hypertrophic and dilated cardiomyopathy. Hybrid Hybridomics (2003) 0.79
Clinical applications of miRNAs in cardiac remodeling and heart failure. Per Med (2010) 0.79
Common variation neighbouring micro-RNA 22 is associated with increased left ventricular mass. PLoS One (2013) 0.78
Natriuretic peptides and the genomics of left-ventricular hypertrophy. Heart Fail Clin (2010) 0.77